An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI
Latest Information Update: 07 Aug 2024
At a glance
- Drugs MT 1002 (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shaanxi Micot Technology Co
- 07 Aug 2024 New trial record